Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Poly ICLC - Oncovir

Next Previous
Drug Profile

Poly ICLC - Oncovir

Alternative Names: DNAJB1 PRKACA; Hiltonol; P.I.C.L.C.; Poly-ICLC; Polyinosinic polycytidylic acid; polyinosinic-polycytidylic acid-polylysine-carboxymethylcellulose; Polyriboinosinic-polyribocytidylic acid

Latest Information Update: 06 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medical University of South Carolina; Oncovir
  • Developer Abramson Cancer Center of the University of Pennsylvania; Augusta University; Bristol-Myers Squibb; Celldex Therapeutics Inc; Icahn School of Medicine at Mount Sinai; Immatics N.V.; Ludwig Institute for Cancer Research; Medical University of South Carolina; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); New York University School of Medicine; OncoQuest; Oncovir; Quest PharmaTech; Roswell Park Cancer Institute; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University Hospitals of Geneva; University of Calgary; University of California, San Diego; University of Pittsburgh; Washington University School of Medicine
  • Class Adjuvants; Antineoplastics; Antivirals; Biopolymers; Oligonucleotides
  • Mechanism of Action 2',5' oligoadenylate synthetase modulators; DDX58 protein modulators; IFIH1 interferon-induced helicase modulators; Immunomodulators; Natural killer cell stimulants; Natural killer T cell stimulants; Proto-oncogene protein c-rel modulators; Proto-oncogene protein c-ret modulators; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer; Flavivirus infections; Orthopoxvirus infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Head and neck cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Sarcoma; Skin cancer; Solid tumours
  • Phase I/II B-cell lymphoma; Breast cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; HIV infections; Non-Hodgkin's lymphoma; Peritoneal cancer
  • No development reported Acute myeloid leukaemia; Anaplastic astrocytoma; Chronic myelomonocytic leukaemia; COVID 2019 infections; Cytomegalovirus infections; Glioma; Influenza virus infections; Liver cancer; Malignant-mesothelioma; Myelodysplastic syndromes; Pancreatic cancer; Smallpox

Most Recent Events

  • 25 Apr 2025 Adverse event and immunogenicity data from the phase Ib ETAPA trial presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 30 Oct 2024 National Institute of Allergy and Infectious Diseases plans a phase I trial for HIV Infections (In volunteers) in Peru in February 2025 (Parentral) (NCT06665646)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Prevention) in USA (IM, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top